Apixaban and Tirofiban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Tirofiban
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines make it harder for your blood to clot, just in different ways. Apixaban (Eliquis) is a blood thinner, and tirofiban is an antiplatelet drug usually given in the hospital, often during heart procedures. When you take them together, their effects add up, so your risk of bleeding goes up too.
Watch for things like unusual bruising, pink or red urine, black stools, bleeding gums, or bleeding that won't stop. If you notice any of these, or feel dizzy or very weak, get medical help right away. The good news is that your care team knows about this combination and watches you closely to keep you safe.
Effect: Additive pharmacodynamic increase in bleeding risk when apixaban (a direct factor Xa inhibitor) is combined with tirofiban (a GP IIb/IIIa antiplatelet agent). Neither is a prodrug; the interaction is purely additive on hemostasis, not metabolic.
- Direction/magnitude: Increased bleeding, potentially serious or fatal. Magnitude not quantified.
- Onset: Unspecified; evidence: theoretical.
- Management: Promptly evaluate any signs of blood loss. Discontinue apixaban with active pathological hemorrhage. Andexanet alfa reverses anti-FXa activity; PCC, aPCC, or rFVIIa may be considered. Apixaban PD effect persists at least 24 hours. Note: PT/INR/aPTT and anti-FXa monitoring are not useful when PCCs are used.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Using apixaban together with antiplatelet medications raises the likelihood of bleeding1. In a patient receiving both anticoagulants and antiplatelet drugs concurrently, any indication or symptom of blood loss should be assessed without delay 2. Apixaban must be stopped in patients experiencing active pathological hemorrhage. Patients should be counseled about the signs and symptoms of blood loss, instructed to report them right away, or to present to an emergency room. Apixaban must be stopped in patients experiencing active pathological hemorrhage. A reversal agent for the anti-factor Xa activity of apixaban exists. The pharmacodynamic activity of apixaban is anticipated to remain for a minimum of 24 hours following the final dose. Consideration may be given to prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, tracking apixaban's anticoagulant effect through a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity is not helpful and is therefore not advised. Absorption of apixaban is decreased by activated oral charcoal, which in turn reduces the apixaban plasma concentration 1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
Keep taking both exactly as prescribed unless your care team tells you otherwise. This combination is often used deliberately in a monitored setting, and your team can manage it safely.
- Learn the warning signs of bleeding: unusual bruising, red or black stools, pink or red urine, coughing or vomiting blood, prolonged bleeding, severe headache, or feeling faint.
- Report any of these immediately or go to an emergency room.
- Your team may monitor you more closely and can stop apixaban if serious bleeding occurs. A reversal agent for apixaban is available if needed.
- Ask your pharmacist before adding any new medicine, including over-the-counter pain relievers like aspirin or ibuprofen.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical study involving high-risk patients following acute coronary syndrome who were treated with aspirin or with aspirin combined with clopidogrel (APPRAISE-2) was stopped ahead of schedule because apixaban produced more bleeding than placebo. Among patients on single antiplatelet therapy, the annual rate of ISTH major bleeding was 2.8% with apixaban compared to 0.6% with placebo, and among those on dual antiplatelet therapy it was 5.9% per year with apixaban versus 2.5% per year with placebo 1.
b) In a clinical trial (ARISTOTLE), among patients taking apixaban, adding aspirin raised the annual bleeding risk from 1.8% to 3.4%, and adding both aspirin and warfarin raised the annual bleeding risk from 2.7% to 4.6%; the use of dual antiplatelet therapy alongside apixaban was limited (2.3%) in this trial 1.
c) A retrospective study found that combining a direct oral anticoagulant (DOAC) with antiplatelet therapy (APT; n=78), compared with DOAC therapy by itself (n=329), did not meaningfully change the rate of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were mostly Caucasian men with a mean age of 63.7 years. Those on concurrent APT had significantly higher mean body mass index (30.7 vs 28.4), higher mean CHA2DS2-VASc score (4.28 vs 3.85), and were more likely to have diabetes (26.9% vs 17.3%) than those given DOAC monotherapy. DOACs were prescribed for treatment of VTE or atrial fibrillation and consisted of apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was used in 94.9% (74 patients), with aspirin 81 mg once daily being the most frequent regimen (69 patients). Additional APT regimens comprised aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg plus clopidogrel 75 mg daily (4 patients) 3.
Common questions
Can I take Apixaban and Tirofiban together?
Taking apixaban with tirofiban adds up their blood-thinning effects and raises your bleeding risk, so know the warning signs of bleeding and report them right away. Your care team monitors this closely and can manage it, so keep taking both as prescribed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Tirofiban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Tirofiban interaction managed?
Keep taking both exactly as prescribed unless your care team tells you otherwise. This combination is often used deliberately in a monitored setting, and your team can manage it safely. Learn the warning signs of bleeding: unusual bruising, red or black stools, pink or red urine, coughing or vomiting blood, prolonged bleeding, severe headache, or feeling faint. Report any of these immediately or g… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Tirofiban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
Keep reading about Apixaban
Keep reading about Tirofiban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist